The Role of Interleukin-37 in the Pathogenesis of Allergic Diseases

Abstract

Cytokines of the interleukin-1 (IL-1) family play an important role in the realization of the protective functions of innate immunity and are the key mediators involved in the pathogenesis of a wide range of diseases, including various manifestations of allergy. The IL-1 family includes more than 11 members. However, the functions of many of them remain to be elucidated. Recently, new members of the IL-1 family have been discovered. In 2000, several independent research groups reported the discovery of a new interleukin of this family, which was named IL-37, or IL-1F7 (according to the new nomenclature). IL-37 was assigned to the IL-1 family based on its structural similarity with other members of this family. The study of its biological properties showed that its activity changes in inflammatory diseases, such as rheumatoid arthritis, psoriasis, as well as allergic diseases (allergic rhinitis, bronchial asthma, and atopic dermatitis). However, unlike most members of the IL-1 family, IL-37 acts as a negative regulator of inflammation. Activation of IL-37 suppresses inflammation, resulting in the suppression of inflammatory cytokines and chemokines, which in turn prevents infiltration of pro-inflammatory cells, mainly eosinophils and neutrophils. The exact molecular and cellular mechanisms of the anti-inflammatory effect of IL-37 in the development of allergic diseases (AD) have not been fully studied. This review summarizes and analyzes the accumulated experimental data on the role of IL-37 in the pathogenesis of AD, such as allergic rhinitis, bronchial asthma, and atopic dermatitis.

Economic Aspects of Application of the Russian Biosimilar Omalizumab in Patients With Atopic Bronchial Asthma of Moderate to Severe Clinical Courses

“…Высокая распространенность, длительное хроническое течение заболевания, необходимость постоянной лекарственной терапии -все это обуславливает высокую социальную значимость БА [6,7]. Астма представляет собой серьезное социально-экономическое бремя для стран с низким и средним уровнем дохода [3].…”

“…На территории РФ в настоящее время зарегистрирован целый ряд ГИБП, таких как бенрализумаб, реслизумаб, дупилумаб, меполизумаб и омализумаб [25]. Эффективность и безопасность данных препаратов доказана в многочисленных клинических исследованиях, они включены в перечень жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП) 5 и федеральные клинические рекомендации 6 .…”